← Eichor
Study identifier: NCT07462897 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of the Effectiveness of a New Generation of Myopia Control Lens on the Progression of Myopia in Children Aged 6 to 14 Years

Condition: Myopia Progression  ·  Sponsor: Essilor International

PhaseNA
Planned participants76
Who can joinAll sexes, 6 Years to 14 Years
Healthy volunteersNo

About this study

The goal of this clinical investigation is to learn how much a new generation of myopia control lens (MCL1 - Myopia Control Lens 1) is helpful in reducing myopia progression in children from 6 to 14 yo. The main questions it aims to answer is: How much this new generation of lens, called MCL1, slows down the growth of the eye? Researchers will compare MCL1 to a former generation of myopia control lens (i.e. MCL2) but with better vision quality. Participants will: * Wear MCL1 on right eye and MCL2 on left eye for 6 months and MCL2 on rigth eye and MCL1 on left eye for the next 6 months; * Visit the hospital at 6 and 12 months for tests; * Answer weekly questionnaires on compliance wearing glasses, quality of vision and out-of-school activities.

This description comes directly from the study's public registry record.

Talk to the study team

Thibaut Chapron, MD  ·  00331 48 03 65 56  ·  tchapron@for.paris

Always discuss trial participation with your own doctor first.

Locations (1)

Département d'Ophtalmologie, Hôpital Fondation Adolphe de RothschildParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07462897